Gene · 148
ADRA1A: adrenoceptor alpha 1A
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. ADRA1A: adrenoceptor alpha 1A. Genes, record 148. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/148
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P35348 | Alpha-1A adrenergic receptor | 466 | 9 | Ensembl, GeneID, HGNC |
Source UniProt
Patents58
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 36834 | P35348 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 36838 | P35348 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 2538 | P35348 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 331 | P35348 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 331 | P35348 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 2538 | P35348 | Espacenet |
| JP 2025062604 A | 2025-04-14 | 3456 | P35348 | Espacenet |
| JP 2025062604 A | 2025-04-14 | 3459 | P35348 | Espacenet |
| JP 2025032204 A | 2025-03-11 | 24236 | P35348 | Espacenet |
| JP 2025032204 A | 2025-03-11 | 24237 | P35348 | Espacenet |
1 to 10 of 58
See all 58 patentsDrugs75
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ALFUZOSIN | CHEMBL709 | Adrenergic receptor alpha-1 agonist | AGONIST | ChEMBL |
| ALFUZOSIN HYDROCHLORIDE | CHEMBL1723 | Adrenergic receptor alpha-1 agonist | AGONIST | ChEMBL |
| ALSEROXYLON | CHEMBL1201454 | Adrenergic receptor alpha antagonist | ANTAGONIST | ChEMBL |
| AVIPTADIL | CHEMBL1981592 | Adrenergic receptor alpha antagonist | ANTAGONIST | ChEMBL |
| BUCINDOLOL | CHEMBL321582 | Adrenergic receptor alpha-1 antagonist | ANTAGONIST | ChEMBL |
| BUCINDOLOL HYDROCHLORIDE | CHEMBL2107546 | Adrenergic receptor alpha-1 antagonist | ANTAGONIST | ChEMBL |
| BUNAZOSIN | CHEMBL188185 | Adrenergic receptor alpha-1 antagonist | ANTAGONIST | ChEMBL |
| CARVEDILOL | CHEMBL723 | Adrenergic receptor alpha-1 antagonist | ANTAGONIST | ChEMBL |
| CARVEDILOL PHOSPHATE | CHEMBL1201167 | Adrenergic receptor alpha-1 antagonist | ANTAGONIST | ChEMBL |
| DABUZALGRON | CHEMBL257978 | Alpha-1a adrenergic receptor partial agonist | PARTIAL AGONIST | ChEMBL |
1 to 10 of 75
See all 75 drugsTrials775
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07577518 | CARVEDILOL | ClinicalTrials.gov | ||
| NCT07572656 | LABETALOL | ClinicalTrials.gov | ||
| NCT07464028 | TERAZOSIN | PHASE2 | ClinicalTrials.gov | |
| NCT07442643 | EPINEPHRINE | ClinicalTrials.gov | ||
| NCT07442071 | EPINEPHRINE | PHASE3 | ClinicalTrials.gov | |
| NCT07432997 | MIDODRINE | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07422948 | MIDODRINE | ClinicalTrials.gov | ||
| NCT07398508 | DROXIDOPA | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07364201 | LABETALOL | ClinicalTrials.gov | ||
| NCT07363343 | LABETALOL | ClinicalTrials.gov |
1 to 10 of 775
See all 775 trialsNIH grants1,058
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | ADRA1A papers | Newest fiscal year |
|---|---|---|---|
| I01BX000740 | Right Heart Function in Health and Chronic Disease | 3 | 2025 |
| P01AG019724 | Frontotemporal Dementia: Genes, Images, and Emotions | 3 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 3 | 2025 |
| R01HL086694 | From GWAS loci to blood pressure genes, variants & mechanisms - Renewal | 3 | 2025 |
| R01HL140067 | Metabolic mechanisms of cardioprotection through alpha-1A adrenergic receptor activation | 3 | 2025 |
| T32GM007569 | Clinical Pharmacology Training Program | 3 | 2025 |
| U24AG021886 | National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD) | 3 | 2025 |
| P30AG066508 | Yale Alzheimer Disease Research Center | 2 | 2025 |
| P30CA068485 | Cancer Center Support Grant | 2 | 2025 |
| P30DK026687 | New York Obesity Research Center | 2 | 2025 |
1 to 10 of 1,058Source NIH's project files
See all 1,058 nih grantsPapers1,657
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Construction of α1A-Adrenoceptor-Based Stationary Phase Triggered by the Ultrahigh Affinity Protein Pair Colicin E7 Dnase /IM7 for Targeted Bioactive Compound Screening in Herba leonuri. | J Sep Sci | 2026 | 42703902 | PubTator, text mining | PubMed |
| ASIV Attenuates Cisplatin-Induced Proximal Tubular Injury by Enhancing Mitochondrial Biogenesis and Mitophagy Through the ADRA1A/AMPK/FOXO3A Pathway. | FASEB J | 2026 | 42687819 | PubTator, text mining | PubMed |
| α 1A-Adrenergic receptor (ADRA1A) signaling signatures as prognostic biomarkers in liver hepatocellular carcinoma: a bioinformatic analysis. | In Silico Pharmacol | 2026 | 42542688 | PubTator, text mining | PubMed |
| RORα-Adra1a: defining a new transcriptional axis in cardiomyocyte biology. | Am J Physiol Heart Circ Physiol | 2026 | 42531559 | PubTator, text mining | PubMed |
| Increased Adrenergic Receptor Expression in Meniere Disease. | Otol Neurotol | 2026 | 42531530 | PubTator, text mining | PubMed |
| Aconitine from Aconiti Lateralis Radix Praeparata (Fuzi) Suppresses Intrahepatic Cholangiocarcinoma via TOP2A: A Study Combining Machine Learning with Functional Validation. | Chin J Integr Med | 2026 | 42448944 | PubTator, text mining | PubMed |
| Spatio-molecular gene expression reflects dorsal anterior cingulate cortex structure and function in the human brain. | Cell Rep | 2026 | 42241279 | PubTator, text mining | PubMed |
| G protein-coupled receptor autoantibody expression patterns in adults with decelerated biological aging mirror pediatric profiles. | BMC Immunol | 2026 | 42237231 | PubTator, text mining | PubMed |
| Neuroimmunological Mechanisms of Xiao-Yao-San Against Chronic Stress-Induced Colorectal Cancer: A Bioinformatics and Single-Cell Sequencing Study. | Cancer Manag Res | 2026 | 41798904 | PubTator, text mining | PubMed |
| Studies and analysis of drug-target interactions by affinity chromatography and related techniques: A review. | J Pharm Anal | 2026 | 41798072 | PubTator, text mining | PubMed |
1 to 10 of 1,657
See all 1,657 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/148
GET https://conductscience.org/api/genes/v1/148/patents?page=2